Proteomics appoints new Director

Life sciences company Proteomics International Laboratories Ltd (PILL, ASX: PIQ) is delighted to announce the appointment of Mr. Roger Moore as a Non-Executive Director of the Company.

The appointment brings key industry and sector experience to the Board as the Company seeks to commercialise its lead diagnostics product, PromarkerD, and expand its analytical services in Asia.

Roger Moore has 40 years experience in the international pharmaceutical industry, including almost 30 years as President of Novo Nordisk Japan (Novo Nordisk is the world’s largest manufacturer of insulin and a global leader in diabetes care). Mr. Moore established Novo’s organisation in Japan as the first employee in 1977, and worked for the company until his retirement as Chairman at the end of 2007. From 2000, Roger Moore was appointed Senior Vice President, Japan and Oceania Region, responsible for Novo Nordisk’s business in Japan, Australia, New Zealand and the Pacific. He was also appointed a member of the Senior Management Board, Novo Nordisk A/S.

In 2007 Mr. Moore was awarded the Knight’s Cross of the Order of the Dannebrog by Queen Margrethe II of Denmark.

Since 2008 he has split his time between Australia and Japan and has worked to assist selected Australian biotech companies and selected Japanese pharma companies in their international business development activities.

PILL managing director Dr Richard Lipscombe stated, this is an important appointment for us following our recent first licensing deal for PromarkerD, our novel diagnostic test for diabetic kidney disease. “Roger’s wealth of knowledge from a career targeting the treatment of diabetes will be invaluable”, he said. Mr. Moore has been providing consultancy services to PILL since October 2015 and will continue to do so on commercial terms.

On joining PILL, Mr. Moore said "I am excited about the potential of PromarkerD to predict diabetic kidney disease, and look forward to helping with its worldwide commercialisation and being part of the continued growth of the Company”.

ENDS

For further information please contact:
Dr Richard Lipscombe  Susan Fitzpatrick-Napier [Media Contact]
Managing Director  Digital Mantra Group
Proteomics International Laboratories Ltd  T: +61 2 8218 2144
T: +61 8 9389 1992  E: team@dmgpr.com
E: enquiries@proteomicsinternational.com
www.proteomicsinternational.com
About Proteomics International Laboratories (PILL)
PILL (ASX: PIQ) is a life science company focused on the area of proteomics – the industrial scale study of the structure and function of proteins. In the last few years, proteins have become the drug class of choice for the pharmaceutical industry because of their intimate role in biological systems. Thus proteomics technology is now playing a key role in understanding disease, from finding new diagnostic biomarkers to determining drug targets, and discovering new biopharmaceutical drugs.

PILL is recognised as a global leader in the field of proteomics. It received the world’s first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the art facilities at the Harry Perkins Institute of Medical Research in Perth, Western Australia. The Company’s business model uses its proprietary technology platform across three integrated areas, each massive growth markets:

1. **Diagnostics**: Biomarkers of disease and personalised medicine - focus on diabetic kidney disease. By 2020 the biomarkers market is estimated to double in size to $45.6 billion, and the personalised medicine market is forecast to be worth over $149 billion.

2. **Analytical services**: Specialist contract research fee-for-service model – focus on biosimilars QC. The global biosimilars market is expected to reach $6.2 billion by 2020, almost trebling from its 2015 level, as it seeks to replicate the multiple billion dollar blockbuster drugs that are coming off patent.

3. **Drug discovery**: Therapeutic peptide drug discovery - focus on painkillers and antibiotics. The global peptide therapeutics market is currently estimated to be worth $18 billion and is expected to increase at over 10% per year during 2016-2025.

In combination these areas offer, respectively, medium term products, near term cash flow, and blue sky potential by harnessing one complementary workflow centred on proteins.